Therapy Class Overview: Rituximab biosimilar
DUBLIN, Mar. 27, 2014 /PRNewswire/ –
Research and Markets
) has announced the addition of the
report to their offering.
Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter!
Inflectra is a biosimilar of Johnson & Johnson’s Remicade, which is approved for RA, Crohn’s disease and several other conditions and had $2 billion in sales in Europe last year. This approval has further increase the optimism of companies developing and marketing biosimilars and the wait for the launch of others in queue Rituxan, Herecptin, Enbrel etc may not be too long. These three drugs alone had worldwide sales of -$21b in 2012.
Commercial success of biosimilars will be depend both on affordability and accessibility assuming that the copy molecule is at par on efficacy, safety and similarity with the branded product. Uptake and marketing strategy of Remicade biosimilar will be closely watched by investors as well as companies developing/marketing Biosimilars. In this report, we have analyzed the market opportunity of rituximab biosimilar.
Key Topics Covered:
1. Executive Summary
2.Ex-US Experience of Biosimilar launch
3.Introduction – Rituxan/ MabThera (rituximab)
4.Opportunities and Threats for Rituximab Biosimilar
5.A brief on Companies Developing Rituximab Biosimilar
6.Our view on Risk/Reward profile of developing Rituximab Biosimilar
7.About the biosimilar spaceDifferent Technologies Deployed By Biosimilar Players
-- Bio-better -- Biogen Idec -- CLL -- DLBCL -- Dr Reddys -- Enbrel -- GA-101 -- Genentech -- MabThera -- NHL -- Obinutuzumab -- Ofatumumab -- RA -- Reditux -- Remicade -- Rituxan -- Roche -- Type II -- anti-CD20 -- biologics -- biosimilar -- life cycle management -- monoclonal antibody -- rituximab
For more information visit http://www.researchandmarkets.com/research/rwdz5w/therapy_clas
Laura Wood , +353-1-481-1716, email@example.com
SOURCE Research and Markets